Código QR (código de barras bidimensional)

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

IntroductionChimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtagene autoleucel (cilta-cel) is a good candidate for...

ver descrição completa

Na minha lista:
Principais autores: Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Carol Ann Huff, Murali Janakiram, Yi-Hsuan Liu, Kevin C. De Braganca, Nicole Lodowski, Jennifer Sander, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Zaina P. Qureshi, Krina K. Patel
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-06-01
coleção:Frontiers in Immunology
Assuntos:
ciltacabtagene autoleucel
cilta-cel
outpatient
car t therapy
CAR T-cell
relapsed or refractory multiple myeloma
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1405452/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados